Key Principles and Recommended Regimens for First-line Antiretroviral Therapy

  • Author: Paul E. Sax, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/5/18 (What's New)

Summary

    Available Integrase Inhibitors
    • 4 INSTIs that have been approved for use in first-line therapy regimens are raltegravir, elvitegravir, dolutegravir, and bictegravir
      • All 4 INSTIs are recommended first-line options in the DHHS guidelines
        • IAS-USA guidelines include only bictegravir and dolutegravir among regimens generally recommended for first-line ART
    Clinical Trials Comparing Integrase Inhibitors
      Choosing Among Integrase Inhibitors

      Action required